ROXI-ASPENNCT07213778
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Nov 8, 2026. The record was updated there on Nov 19, 2026; versions filed since then are not listed here yet.
All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 49 → 57 locations
- Minor Study sites: 49 to 51
- Minor Trial sites expanded: 46 → 49 locations
- Notable Eligibility criteria expanded, about 7 words
- Trial sites expanded: 36 → 46 locations
- Minor Study sites: 34 to 36v14
- Minor Study sites: 32 to 34v13
- Minor Trial sites expanded: 28 → 32 locationsv12
- Minor Trial sites expanded: 23 → 28 locationsv11
- Minor Trial sites expanded: 19 → 23 locationsv10
- Notable Primary endpoint(s) modified
- Trial sites expanded: 16 → 19 locations
- Secondary endpoints revised (14)
- Minor Study sites: 14 to 16v8
- Minor Study sites: 13 to 14v7
- Minor Trial sites expanded: 10 → 13 locationsv6
- Minor Study sites: 9 to 10v5
- Minor Study sites: 5 to 9v4
- Minor Study sites: 2 to 5v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Primary completion date: Jul 16, 2027 to May 17, 2027
- Start date changed from estimate of Dec 5, 2025 to Nov 24, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of the composite endpoint of symptomatic VTE and all-cause death
Timeframe: Through day 30 visit
Secondary (14)
Time to first event of the composite endpoint of symptomatic VTE and all-cause death
Incidence of confirmed symptomatic Deep Vein Thrombosis (DVT)
Incidence of confirmed Pulmonary Embolism (PE)
Incidence of all-cause death
Time to first event of the confirmed symptomatic DVT
Show 9 moreShow less
Time to first event of the confirmed PE
Time to the all-cause death
Incidence of the composite endpoint of major bleeding and Clinically Relevant Non-Major (CRNM) bleeding
Incidence of minor bleeding
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Incidence of Anti-drug Antibody (ADA) to REGN7508
Magnitude of ADA to REGN7508
Concentrations of REGN7508
Arms and interventions
REGN7508 and PlaceboExperimental
Placebo and ASAActive comparator
Drugs: REGN7508, Acetylsalicylic Acid (ASA), Placebo
Sites
57 sites in 5 countries
United States 42, Spain 6, Malaysia 5, Greece 3, Moldova 1